MarketsNotableReported
5.2
ArriVent shares plunge 47% after China-licensed cancer drug fails Phase 3 trial
South China Morning PostLO·US · CN·2 days ago
Researchers at a Chinese university have developed a wearable prototype combining a glucose sensor and insulin micropump in a single coin-sized device, tested only on mice. The innovation could simplify diabetes management by replacing two-patch systems, but human trials and regulatory approval remain distant. This is an early-stage scientific advance with no immediate market impact.